Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x

A method for treating and/or reducing the incidence of a disease that develops and/or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII (FVIIIa), the method comprising:

• administering to a subject a bispecific antibody that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X at a weekly loading dose of 4.5 mg/kg of the antibody for four weeks;
• and thereafter administering a maintenance dose of the antibody to the subject one or more times, the maintenance dose being 9 mg/kg of the antibody which is administered every four weeks or every month in two or four divided doses.

A method for treating and/or reducing the incidence of a disease that develops and/or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII (FVIIIa), the method comprising:

• administering to a subject a bispecific antibody that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X at a weekly loading dose of 6 mg/kg of the antibody for four weeks;
• and thereafter administering a maintenance dose of the antibody to the subject one or more times, the maintenance dose being 12 mg/kg of the antibody which is administered every four weeks or every month in two or four divided doses.